Vergent Bioscience Awarded National Cancer Institute Phase 2 Grant to Advance Clinical Development of VGT-309 in Lung Cancer
Vergent Bioscience , a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that the National Cancer Institute (NCI) of the National Institutes of Health (NIH) has awarded the company a Small Business Innovation Research (SBIR) grant of nearly $2 million (Award Number R44CA277890).
- Vergent Bioscience , a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that the National Cancer Institute (NCI) of the National Institutes of Health (NIH) has awarded the company a Small Business Innovation Research (SBIR) grant of nearly $2 million (Award Number R44CA277890).
- The grant will help fund a Phase 2 clinical study evaluating the companys targeted fluorescent imaging agent, VGT-309, for intraoperative imaging of tumors in patients undergoing lung cancer surgery.
- We are grateful to the NCI for their support and to the team at the University of Pennsylvanias Perelman School of Medicine for conducting this Phase 2 study.
- The company is first evaluating VGT-309 in lung cancer, with the potential to expand its application to a wide range of solid tumors.